DK1152012T3 - Tuberkulosevacciner - Google Patents

Tuberkulosevacciner

Info

Publication number
DK1152012T3
DK1152012T3 DK01109298T DK01109298T DK1152012T3 DK 1152012 T3 DK1152012 T3 DK 1152012T3 DK 01109298 T DK01109298 T DK 01109298T DK 01109298 T DK01109298 T DK 01109298T DK 1152012 T3 DK1152012 T3 DK 1152012T3
Authority
DK
Denmark
Prior art keywords
tuberculosis vaccines
vaccines
tuberculosis
epitopes
esat
Prior art date
Application number
DK01109298T
Other languages
Danish (da)
English (en)
Inventor
Ajit Lalvani
Roger Hamilton Brookes
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10803428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1152012(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of DK1152012T3 publication Critical patent/DK1152012T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
DK01109298T 1996-11-25 1997-11-25 Tuberkulosevacciner DK1152012T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9624456.1A GB9624456D0 (en) 1996-11-25 1996-11-25 Assay method
PCT/GB1997/003222 WO1998023960A1 (en) 1996-11-25 1997-11-25 Assay method for peptide specific t-cells

Publications (1)

Publication Number Publication Date
DK1152012T3 true DK1152012T3 (da) 2007-11-26

Family

ID=10803428

Family Applications (2)

Application Number Title Priority Date Filing Date
DK01109298T DK1152012T3 (da) 1996-11-25 1997-11-25 Tuberkulosevacciner
DK97913336T DK0941478T4 (da) 1996-11-25 1997-11-25 Assaymetode for peptidspecifikke T-celler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK97913336T DK0941478T4 (da) 1996-11-25 1997-11-25 Assaymetode for peptidspecifikke T-celler

Country Status (11)

Country Link
US (3) US7575870B1 (de)
EP (2) EP1152012B1 (de)
JP (1) JP4094674B2 (de)
AT (2) ATE213068T1 (de)
AU (1) AU728357C (de)
CA (1) CA2272881C (de)
DE (2) DE69737956T2 (de)
DK (2) DK1152012T3 (de)
ES (1) ES2172773T5 (de)
GB (1) GB9624456D0 (de)
WO (1) WO1998023960A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
AU6480999A (en) 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
GB9923306D0 (en) 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
GB0006692D0 (en) * 2000-03-20 2000-05-10 Glaxo Group Ltd Epitopes
AU2001256999A1 (en) * 2000-04-12 2001-10-30 Wisconsin Alumni Research Foundation. A method for making an hiv vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
DE10125730A1 (de) * 2001-05-17 2002-11-21 A I D Autoimmun Diagnostika Gm Verfahren zum Nachweis von Erregern und durch diese induzierten zellulär produzierten Stoffen im lebenden Organismus
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
NZ545364A (en) * 2003-09-05 2009-06-26 Genencor Int HPV CD8+ T-cell epitopes
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
CN102430111B (zh) 2004-04-28 2018-03-02 英国技术集团国际有限公司 与腹部疾病有关的表位
EP1781313A4 (de) * 2004-06-17 2009-08-26 Beckman Coulter Inc Mycobacterium tuberculosis epitope und anwendungsverfahren dafür
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
GB0619853D0 (en) * 2006-10-06 2006-11-15 Oxford Immunotec Ltd Preparation method
DE102007052517A1 (de) 2007-10-29 2009-04-30 Autoimmun Diagnostika Gmbh ELISPOT-Verfahren mit zwei Filtersystemen
GB2455108A (en) * 2007-11-28 2009-06-03 Circassia Ltd T-Cell dependent method for detecting non-allergic or intrinsic disorders
EP2353008A2 (de) 2008-09-22 2011-08-10 Oregon Health and Science University Verfahren zum nachweis einer infektion mit mycobacterium tuberculosis
GB0906215D0 (en) 2009-04-09 2009-05-20 Lalvani Ajit Diagnostic test
EP3360566B1 (de) 2009-11-20 2019-12-25 Oregon Health&Science University Verfahren zum erkennen einer infektion mit dem mycobakterium tuberculosis
IT1403092B1 (it) 2010-12-01 2013-10-04 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio della mucormicosi.
EP2667811B1 (de) 2011-01-27 2015-12-30 Cryosa, Llc Vorrichtung zur behandlung von obstruktiver schlafapnoe durch kryolyse von adipösen geweben
FR2983213B1 (fr) 2011-11-30 2015-03-06 Commissariat Energie Atomique Procede de mesure en temps reel des secretions individuelles d'une cellule
GB201122297D0 (en) 2011-12-23 2012-02-01 Retroscreen Virology Ltd Vaccine - screening method
EP2795321A2 (de) * 2011-12-23 2014-10-29 Retroscreen Virology Ltd Impfstoffscreeningverfahren
US9678071B2 (en) 2012-01-12 2017-06-13 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
IN2014DN08394A (de) * 2012-03-23 2015-05-08 Esteve Labor Dr
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
EP3134730A4 (de) 2014-04-24 2018-01-17 Immusant Inc. Verfahren zur diagnose von zöliakie mithilfe von zirkulierenden zytokinen/chemokinen
WO2016053741A1 (en) 2014-10-01 2016-04-07 Cryosa, Llc Apparatus and methods for treatment of obstructive sleep apnea utilizing cryolysis of adipose tissues
WO2016081869A2 (en) 2014-11-21 2016-05-26 Immusant, Inc. Peptides for use in treatment and diagnosis of type 1 diabetes
FR3033333A1 (fr) 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
EP4257976A3 (de) 2016-09-22 2024-01-24 Pace Diagnostics, Inc Mycobacterium-tuberculosis-proteine in diagnostischen tests und vorrichtungen zur erkennung und diagnose von tuberkulose
US10245320B2 (en) 2016-09-30 2019-04-02 Enzo Biochem, Inc. Immunomodulatory pharmaceutical compositions and methods of use thereof
ES2950436T3 (es) 2016-12-14 2023-10-10 Becton Dickinson Co Métodos y composiciones para obtener una valoración de tuberculosis en un sujeto
WO2019018607A1 (en) 2017-07-20 2019-01-24 Enzo Biochem, Inc. IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF
WO2020142519A1 (en) 2018-12-31 2020-07-09 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
KR102182555B1 (ko) * 2019-03-14 2020-11-24 한국과학기술연구원 T 세포 면역 반응 활성화를 위한 암 치료용 암항원 발굴 플랫폼
US20220214332A1 (en) 2019-05-30 2022-07-07 Oregon Health & Science University Methods for Detecting A Mycobacterium Tuberculosis Infection
WO2021168367A1 (en) 2020-02-19 2021-08-26 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea
CN111856020B (zh) * 2020-06-19 2022-09-27 南方医科大学南方医院 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用
WO2023130069A2 (en) 2021-12-30 2023-07-06 Cryosa, Inc. Systems and methods for treatment of obstructive sleep apnea

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0296158B1 (de) 1986-03-06 1992-06-17 Commonwealth Scientific And Industrial Research Organisation In-vitro-testverfahren zum nachweis zellulärer immunresponsen
DK79893D0 (da) 1993-07-02 1993-07-02 Statens Seruminstitut New vaccine
US5955077A (en) 1993-07-02 1999-09-21 Statens Seruminstitut Tuberculosis vaccine
US20020136733A1 (en) 1994-03-31 2002-09-26 Hill Adrian Vivian Sinton Malaria peptides
WO1997000067A1 (en) * 1995-06-15 1997-01-03 University Of Victoria Innovation And Development Mycobacterium tuberculosis dna sequences encoding immunostimulatory peptides
DE19525784A1 (de) * 1995-07-14 1997-01-16 Boehringer Mannheim Gmbh Autoreaktive Peptide aus der humanen Glutamin-Decarboxylase (GAD)
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US5939281A (en) 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
AU6480999A (en) * 1998-11-04 2000-05-22 Isis Innovation Limited Tuberculosis diagnostic test
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
WO2002054072A2 (en) 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
GB0215710D0 (en) * 2002-07-05 2002-08-14 Isis Innovation Diagnostic method

Also Published As

Publication number Publication date
JP4094674B2 (ja) 2008-06-04
EP1152012A1 (de) 2001-11-07
DK0941478T4 (da) 2007-10-08
WO1998023960A1 (en) 1998-06-04
GB9624456D0 (en) 1997-01-15
DE69737956T2 (de) 2008-04-17
US9360480B2 (en) 2016-06-07
ES2172773T5 (es) 2008-01-16
DK0941478T3 (da) 2002-07-01
EP0941478A1 (de) 1999-09-15
JP2001505568A (ja) 2001-04-24
EP0941478B1 (de) 2002-02-06
CA2272881A1 (en) 1998-06-04
ATE213068T1 (de) 2002-02-15
AU728357C (en) 2001-11-01
ES2172773T3 (es) 2002-10-01
US8617821B2 (en) 2013-12-31
AU5063298A (en) 1998-06-22
EP1152012B1 (de) 2007-07-25
CA2272881C (en) 2007-10-09
DE69710360T2 (de) 2002-11-14
DE69710360D1 (de) 2002-03-21
DE69710360T3 (de) 2008-01-17
DE69737956D1 (de) 2007-09-06
EP0941478B2 (de) 2007-06-06
AU728357B2 (en) 2001-01-04
US7575870B1 (en) 2009-08-18
US20100203568A1 (en) 2010-08-12
ATE368052T1 (de) 2007-08-15
US20140087399A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
DE69737956D1 (de) CD8 Tuberkulose Impfstoffe
EP0656788A4 (de) Hla bindepeptide und seine verwendungen
BR9406652A (pt) Composição
EP1189624A4 (de) Hla-bindende peptide und deren verwendung
DE69733352D1 (de) Hla-a2.1 bindende peptide und deren verwendung
PT807178E (pt) Proteinas de micobacterias, microrganismos que as produzem e suas utilizacoes vacinicas e para a deteccao da tuberculose
ATE536187T1 (de) Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
DK1007686T3 (da) Tuberkulosevaccine
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20005050D0 (no) Fusjonsproteiner fra Mycobacterium Tuberculosis-antigener og deres anvendelse
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
TW396764U (en) The hair curlers used for permanent
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
GB9409985D0 (en) Vaccine against mycobacterial infections
DE58909762D1 (de) Bacillus thuringiensis Transformation
DK1214088T3 (da) Proteiner udtrykt af Mycobacterium tuberculosis og ikke af BCG og anvendelse heraf som diagnostiske reagenser og vacciner
ATE429247T1 (de) Hla-bindende peptide und ihre verwendungen
ATE212129T1 (de) Präsentation von aus lipoarabinomannan bestehenden antigenen an t-zellen durch cd1 moleküle
NO20005081D0 (no) Et polypeptid inneholdende aminosyren fra et N-terminalt kolinbindende protein A-truncat, vaksine avledet derfra og anvendelser derav
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
DK469188A (da) Fremgangsmaade og indretning til tilvejebringelse af personlig luftkonditionering
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium
KR940023996U (ko) 이·미용용 중화제 분사기
ID21667A (id) Komposisi ii antigen bakteri dan komposisi vaksin